BioCentury | Nov 7, 2020
Regulation
Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate
...have problem characterizing it as overwhelmingly positive,” added Madhav Thambisetty, senior investigator and chief of the National Institute on Aging’s...